| Net Cash Provided by (Used in) Operating Activities |
$4,000 |
USD |
|
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$2,696,000 |
USD |
|
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
1,000 |
shares |
|
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
1,000 |
shares |
|
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
|
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$2,700,000 |
USD |
|
Q1 2025 |
Q1 2025 |
| Interest Paid, Excluding Capitalized Interest, Operating Activities |
$787,000 |
USD |
9738% |
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Valuation Allowance |
$991,000 |
USD |
|
Q3 2025 |
Q3 2025 |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.8 |
pure |
|
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$865,000 |
USD |
|
Q3 2025 |
Q3 2025 |
| Deferred Federal Income Tax Expense (Benefit) |
$0 |
USD |
|
Q3 2025 |
Q3 2025 |
| Additional Paid in Capital |
$3,897,000 |
USD |
|
Q3 2025 |
Q3 2025 |
| Current State and Local Tax Expense (Benefit) |
$0 |
USD |
|
Q3 2025 |
Q3 2025 |
| Current Federal Tax Expense (Benefit) |
$0 |
USD |
|
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$991,000 |
USD |
|
Q3 2025 |
Q3 2025 |
| Deferred State and Local Income Tax Expense (Benefit) |
$0 |
USD |
|
Q3 2025 |
Q3 2025 |